Fenoglietto Pascal, Laliberte Benoit, Allaw Ali, Ailleres Norbert, Idri Katia, Hay Meng Huor, Moscardo Carmen Llacer, Gourgou Sophie, Dubois Jean-Bernard, Azria David
Département d'Oncologie Radiothérapie, CRLC Val d'Aurelle-Paul Lamarque, Montpellier, France.
Radiother Oncol. 2008 Jul;88(1):77-87. doi: 10.1016/j.radonc.2007.12.011. Epub 2008 Jan 22.
To compare the dose coverage of planning and clinical target volume (PTV, CTV), and organs-at-risk (OAR) between intensity-modulated (3D-IMRT) and conventional conformal radiotherapy (3D-CRT) before and after internal organ variation in prostate cancer.
We selected 10 patients with clinically significant interfraction volume changes. Patients were treated with 3D-IMRT to 80 Gy (minimum PTV dose of 76 Gy, excluding rectum). Fictitious, equivalent 3D-CRT plans (80 Gy at isocenter, with 95% isodose (76 Gy) coverage of PTV, with rectal blocking above 76 Gy) were generated using the same planning CT data set ("CT planning"). The plans were then also applied to a verification CT scan ("CT verify") obtained at a different moment. PTV, CTV, and OAR dose coverage were compared using non-parametric tests statistics for V95, V90 (% of the volume receiving 95 or 90% of the dose) and D50 (dose to 50% of the volume).
Mean V95 of the PTV for "CT planning" was 94.3% (range, 88-99) vs 89.1% (range, 84-94.5) for 3D-IMRT and 3D-CRT (p=0.005), respectively. Mean V95 of the CTV for "CT verify" was 97% for both 3D-IMRT and 3D-CRT. Mean D50 of the rectum for "CT planning" was 26.8 Gy (range, 22-35) vs 43.5 Gy (range, 33.5-50.5) for 3D-IMRT and 3D-CRT (p=0.0002), respectively. For "CT verify", this D50 was 31.1 Gy (range, 16.5-44) vs 44.2 Gy (range, 34-55) for 3D-IMRT and 3D-CRT (p=0.006), respectively. V95 of the rectum was 0% for both plans for "CT planning", and 2.3% (3D-IMRT) vs 2.1% (3D-CRT) for "CT verify" (p=non-sig.).
Dose coverage of the PTV and OAR was better with 3D-IMRT for each patient and remained so after internal volume changes.
比较前列腺癌患者体内器官变化前后,调强放疗(3D-IMRT)与传统适形放疗(3D-CRT)在计划靶区(PTV)、临床靶区(CTV)以及危及器官(OAR)的剂量覆盖情况。
我们选取了10例具有临床显著分次间体积变化的患者。患者接受3D-IMRT治疗,剂量为80 Gy(PTV最小剂量为76 Gy,不包括直肠)。使用相同的计划CT数据集(“CT计划”)生成虚拟的等效3D-CRT计划(等中心处80 Gy,PTV的95%等剂量线(76 Gy)覆盖,直肠在76 Gy以上进行遮挡)。然后将这些计划也应用于在不同时刻获取的验证CT扫描(“CT验证”)。使用非参数检验统计量比较PTV、CTV和OAR的剂量覆盖情况,指标包括V95、V90(接受95%或90%剂量的体积百分比)以及D50(体积的50%所接受的剂量)。
“CT计划”中PTV的平均V95为94.3%(范围88 - 99),而3D-IMRT和3D-CRT分别为89.1%(范围84 - 94.5)(p = 0.005)。“CT验证”中CTV的平均V95在3D-IMRT和3D-CRT中均为97%。“CT计划”中直肠的平均D50为26.8 Gy(范围22 - 35),而3D-IMRT和3D-CRT分别为43.5 Gy(范围33.5 - 50.5)(p = 0.0002)。对于“CT验证”,该D50在3D-IMRT和3D-CRT中分别为31.1 Gy(范围16.5 - 44)和44.2 Gy(范围34 - 55)(p = 0.006)。“CT计划”中两个计划直肠的V95均为0%,“CT验证”中3D-IMRT为2.3%,3D-CRT为2.1%(p = 无显著性差异)。
对于每位患者,3D-IMRT在PTV和OAR的剂量覆盖方面更好,并且在体内体积变化后依然如此。